<span style="line-height: 20.8px;">Bill Ackman, chief executive officer of hedge fund firm Pershing Square Capital Management L.P., probably won&#39;t like to be reminded of the recent events. From the hedge fund manager&#39;s perspective, almost everything went wrong. For one thing, embattled drug company&nbsp;</span><strong style="line-height: 20.8px;">Valeant Pharmaceuticals International, Inc.</strong><span style="line-height: 20.8px;">&nbsp;(NYSE:</span><a href="http://seekingalpha.com/symbol/VRX" style="line-height: 20.8px;" title="Valeant Pharmaceuticals International, Inc.">VRX</a><span style="line-height: 20.8px;">) got kicked to the curb again last week after short seller Andrew Left of Citron Research announced that he&nbsp;</span><a href="http://seekingalpha.com/article/3988720-valeant-pharmaceuticals-priced-disaster" style="line-height: 20.8px;">reinstated his Valeant short</a><span style="line-height: 20.8px;">&nbsp;and said that he thinks Valeant is &quot;a zero now&quot;.</span>